Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Ascelia Pharma AB, Press Conference

By Inderes10/12/2026, 6:30 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Andreas Norlin
00:02 - 04:53

Welcome everyone on this Monday morning to our update following our Type A meeting with the FDA on the call today. This morning, we have Andreas Norlin, Chief Scientific Officer, and myself, Magnus, co-founder and CEO of Ascelia Pharma. On this call, we will be making forward-looking statements regarding this brief update. We will start by having Andreas go through the key outcomes of the Type A meeting. After that, I will talk about how the outcome translates into our strategic priorities with Orviglance before opening up for questions. Andreas, please go ahead. Thank you, Magnus. So overall, we view the Type A meeting as an important and constructive step forward for Orviglance. So while the FDA maintains its position that additional clinical evidence will be required for approval, the meeting substantially reduced uncertainty around the product quality and clinical aspects of the Complete Response Letter. On the product quality side, we achieved a clear understanding of the FDA's expectations and reached alignment on the path forward and, importantly, on the clinical side. The discussion moved beyond the requirement of conducting a completely new clinical trial. The FDA acknowledged the medical need, the favorable safety profile, and the technical performance of Orviglance as a T1-enhancing contrast agent. But most importantly, the meeting identified an alternative approach that could potentially generate additional clinical evidence required for approval. As a result, we now have greater clarity, reduced regulatory uncertainty, and greater flexibility in evaluating the most efficient path toward U.S. approval than we had before the meeting. approval than we had before the meeting. The first positive outcome from the meeting relates to product quality. FDA and Ascelia Pharma thoroughly discussed the issues raised in the CRL relating to specifications and analytical methods for the drug product, and alignment was reached on the proposed strategy to address the FDA observations. This is important because it removes a significant area of uncertainty. The regulatory expectations are now understood and implementation activities have already started. While work remains, we think the meeting established a clear and actionable path to resolve the product quality component of the Complete Response Letter. The most important outcome of the meeting was on the clinical and regulatory side. In the Complete Response Letter, FDA's recommendation was essentially to conduct a new clinical study with new patients. Following the discussions in the Type A meeting, the FDA confirmed that this remains one possible route. However, and very importantly, the agency also acknowledged an alternative approach. Specifically, FDA indicated that additional clinical evidence could potentially be generated through a new evaluation of the existing SPARKLE image database using a different primary endpoint than originally used. We view this as a significant and encouraging development, rather than having only a single path forward. Instead of relying on a completely new clinical study, there is now the possibility of leveraging the substantial clinical data that have already been generated. Additional work is still required, and our next step is to evaluate potential endpoints that could appropriately address FDA's concerns. And before any image reading process is initiated, alignment with the FDA on the selected endpoint would be obtained. So while the FDA continues to require additional clinical evidence, the meeting materially changed our understanding of how that evidence may potentially be generated. We believe that opening the possibility to use the existing SPARKLE database represents a meaningful opportunity and a substantially more favorable position than the original recommendation of conducting an entirely new clinical study. This is an opportunity we are now actively evaluating. To summarize, the key takeaway is that the meeting changed the conversation from requiring a new clinical study. Clinical studies required to. There may be more than one path to generate the clinical evidence needed for approval. Combined with the alignment achieved on product quality, we believe this represents an important reduction in regulatory uncertainty and a positive development for the Orviglance program in the US. So I will now give the word back to Magnus to talk about our strategic priorities for Orviglance.

Magnus Corfitzen
04:54 - 06:57

Thank you, Andreas. So as Andreas presented to us. The Type A meeting provided clarity on what the FDA wants in order to approve Orviglance. It was a valuable meeting that provided us with more options, confirmed the unmet medical need, and addressed that there are no major safety concerns. We are confident in the strength of our Orviglance data and that Orviglance will be an attractive option for patients where use of gadolinium may be medically inadvisable. I'd like to share our key strategic priorities for Orviglance. We continue the partnering process given the changed situation. The deal structure would likely involve some development activities and not just commercialization, which was the core focus. Previously, as Andreas presented, we are evaluating the most appropriate endpoint for a new read of SPARKLE images that could lead to FDA approval. This would be the most efficient path to approval in the US. Thirdly, we will talk with European regulators to find out if Orviglance can be approved in Europe with the existing data and application. It has been the plan all along to go to Europe after the US process. And if we have a data package that supports approval in Europe, it would be value destruction not to pursue this opportunity. So, given the situation and cost of capital, we think these priorities will generate the most shareholder value. We expect to be in a different situation than where we are now. But I think it's important to focus on. We came out of the Type A meeting with more options and support than what we had when we went into the meeting. We have some clear priorities for Orviglance to generate value, and that is what we're focusing on as we move ahead. That concludes our brief update here, and we would like to open up for questions.

Operator
06:58 - 07:15

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Frederik Thor from Redeye. Please go ahead.

Frederik Thor
07:17 - 07:34

Hello and thank you. So my first question is regarding the rationale. Why is a new endpoint necessary? And is it a totally different endpoint, or is it somewhat similar to the previous primary endpoint? Is it to reduce post-hoc risk or something else?

Andreas Norlin
07:37 - 08:18

So, yes. Yes. Thanks for the question. A new endpoint would be a way to address what you described as reducing the post hoc risk. That is a good way of describing it. It will do that. The exact type of endpoint remains to be evaluated, but the important thing is that the FDA has opened up this opportunity. It is also important in this context that they acknowledged the technical performance of Orviglance. And they agree that we have demonstrated that it actually works very well as a T1-enhancing contrast agent.

Frederik Thor
08:21 - 08:44

And also, in relation to that, if they mentioned their general policy, maybe we can talk a bit about your impression before the meeting regarding the CRL. I mean, it seems that you had assumed a more flexible approach. We just said that it has changed in some way or. Yes, you can talk a bit more about that in general.

Andreas Norlin
08:45 - 09:04

Yeah. Good question. Well, we submitted under the impression that our approach was acceptable based on the discussions and the meetings we had with the FDA prior to the NDA submission, and I think that we will end there. So.

Frederik Thor
09:06 - 09:25

And also, maybe a final question, as you mentioned here, that you will select your endpoint and that you will discuss this with the FDA before a new filing, if I understand it correctly. So, what is the process? What type of meeting would that be? What is the timeline and so on.

Andreas Norlin
09:26 - 10:10

It is a Type C meeting. The timeline is, of course, first we need to identify what we believe is an appropriate endpoint. And that shouldn't take too long. And then we need to prepare some work. I do not think we should. I cannot speculate on that. Exactly. I think it is better to say that we will work as quickly as we can, but the exact timeline is difficult to define today. But it is a Type C process. And of course, we will also work in parallel so that we are prepared or ready to start a new study once we have had a meeting and confirm the approach with the FDA.

Magnus Corfitzen
10:12 - 10:26

To complement that, as I said, we do not have a timeline yet, but our ambition is that the current financing should be sufficient to get that clarity from the FDA.

Frederik Thor
10:29 - 10:43

And in terms of endpoints, are there endpoints available that you can use with the current data, so to speak? What type and how many established endpoints are there that could be used?

Andreas Norlin
10:45 - 10:53

There are a few ideas on the table. One or two that we believe are feasible.

Magnus Corfitzen
10:57 - 10:59

We will come back once we have more information.

Frederik Thor
11:02 - 11:03

That is all for me. Thank you.

Magnus Corfitzen
11:03 - 11:04

Yeah. Thanks, Frederik.

Operator
11:08 - 11:14

The next question comes from Maria Carlson-Osipova from Carnegie. Please go ahead.

Maria Carlson-Osipova
11:16 - 11:29

Hi. Hello. Thank you. Just building on Fredrik's question here. I have not really understood, could you clarify the current financing situation? Where do you think it could take you? Magnus, you mentioned it briefly in your answer.

Magnus Corfitzen
11:31 - 11:44

Sorry, could you repeat the question? I think we have some problems hearing you. Maria, can you?

Maria Carlson-Osipova
11:44 - 11:46

Repeat? Do you hear me now? Maybe.

Magnus Corfitzen
11:47 - 11:47

Yeah.

Maria Carlson-Osipova
11:48 - 12:02

Yeah. Sorry. I think it is a bit unclear. Anyway, I was going to ask a question here: could you clarify the current financing situation and where that can take you? You answered a little bit to Frederik, but it was not really clear there.

Magnus Corfitzen
12:03 - 12:06

Yeah. So the current financing brings us into Q2 next year.

Maria Carlson-Osipova
12:07 - 12:19

All right. And what stands between you and actually aligning the study design with the whole Type A meeting process? What have you begun doing already? What steps have you undertaken?

Andreas Norlin
12:22 - 12:58

So your question is how far we have gotten in the planning. Yeah. Okay. So we have initiated the review of opportunities. I think it is a good idea to bring in our advisors, colleagues, and others that have experience with these kinds of studies and develop that further before we approach the FDA. So the process is ongoing.

Maria Carlson-Osipova
13:01 - 13:14

All right. Thank you. And last one for me, you mentioned you did not want to speculate on timelines with the FDA. Would you like to speculate a bit on the timelines with Europe? When should we expect any meetings and feedback from the European process?

Magnus Corfitzen
13:15 - 13:42

Yes, I think we will. We will do that. You know, we will provide an update when we have the meeting, instead of setting a specific timeline. So obviously, we are working very hard to manage both the FDA and the European process. I think for the European process, we have a lot of the information available. I think we will balance those activities, and we will come back regarding the timeline when we know more.

Maria Carlson-Osipova
13:45 - 13:47

All right. Thank you. That will be all for me.

Magnus Corfitzen
13:48 - 13:48

Thank you, Maria.

Operator
13:52 - 13:57

The next question comes from Georg Tikhonov Bjerke from ABG Sundal Collier. Please go ahead.

Georg Tikhonov Bjerke
14:01 - 14:49

Good morning and thank you for taking my questions. I have a couple of questions remaining, please. So just to establish the visibility on this alternative pathway. In light of the most recent feedback, how confident are you that a prospective analysis of the existing SPARKLE data will be sufficient for approval? Of course, provided that you find an endpoint that can be used. Then secondly, with this scenario, what would be the earliest realistic timeline for bringing Orviglance to the US market? Thank you.

Andreas Norlin
14:51 - 15:01

So I think you asked first how confident we are that we can do a new analysis using a new endpoint. Was that correct?

Georg Tikhonov Bjerke
15:02 - 15:10

Yes, that is correct. Just to clarify the opportunity.

Andreas Norlin
15:10 - 15:52

It is, of course, a new situation for us. So we need to consider this carefully. But we view it as a very interesting and encouraging option because there is a wealth of information in the images. And if we can find a way to extract that information in a way that is sufficiently different from what we did before, that would most likely satisfy the requirements and expectations of the FDA. But there is work remaining. So before we have more clarity, we cannot say much more than that, but we are hopeful that this is a viable path forward.

Magnus Corfitzen
15:54 - 16:02

It was clearly described in the minutes that the FDA considered this a viable path forward.

Georg Tikhonov Bjerke
16:06 - 16:08

Great. Thank you.

Operator
16:13 - 16:20

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
16:22 - 18:19

Yeah. There are some questions here. One question is whether we will make the FDA minutes publicly available. In line with what is customary and what other companies do, we will not make them publicly available. There is a lot of proprietary information there that would not be in the interest of Ascelia Pharma to share openly. So that is not something that we will be doing. There is another question related to elaborating on the partnering process. As we have said before, even after receiving the Complete Response Letter, there was continued interest from potential partners. And that has not changed. We continue the partnering process. This is obviously a different situation because it requires more investment and follows a different timeline for approval. On the other hand, we obtained validation on some important parameters. So, that means that the partner has less risk than an asset that has not been through this FDA review process. So I think there are some positives and some negatives. Our focus is on engaging with potential partners and bringing the partnership process to a signing at some point. So I think it is a different situation. But we believe we should push ahead with the partnering process and see where we stand. There is another question here. When can we expect the next update regarding the path forward with the FDA? Andreas, do you have any thoughts on that?

Andreas Norlin
18:20 - 18:56

I, of course, want us all to move ahead as quickly as possible. And we need to find a solution within the coming months. What is the timeframe? Yeah. Before the end of Q2. But I don't think we can say specifically when we expect to have clarity. And with that, I mean, when we have had the next conversation with the FDA about these endpoints and the plan ahead, it cannot wait too long. Let's say that.

Magnus Corfitzen
18:56 - 19:51

No, I can assure you this is a very high priority. And we will keep the investors updated as we progress. When we have strong confidence in a relevant endpoint, etc. . As we engage with the FDA, there will be updates throughout that process. So there are no more questions. So thank you all for joining us this Monday morning. As you know, to round off, I think we came out of the meeting a lot better than we went into the meeting. I think there are good reasons to believe that we can have an efficient path for approval. Despite this Complete Response Letter, that is what we are pursuing and prioritizing. And we will keep you updated as we move forward. Thank you. And.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…